ReviewJournal of pain research2017
Treatment of chronic low back pain - new approaches on the horizon.
Review in Journal of pain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07296653 (Efficacy of Prolotherapy in Acupoints in Chronic Non-specific Low Back Pain), which is not on this map. Cited by 67 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Prolotherapy in Acupoints in Chronic Non-specific Low Back Pain (cLBP) - A Randomized Control Trial
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- The efficacy and safety of condoliase for lumbar disc herniation: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Acupuncture for the Management of Low Back Pain.Current pain and headache reports · 2021Pooled it
- Assessing the effectiveness of the SOLIO Alfa Cure Plus device in treating low back pain: a randomized controlled study.Journal of orthopaedic surgery and research · 2025Trial
- Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies.Pharmacological reports : PR · 2021Trial
- Comparison of efficacy of corticosteroid injection versus extracorporeal shock wave therapy on inferior trigger points in the quadratus lumborum muscle: a randomized clinical trial.BMC musculoskeletal disorders · 2020Trial
- Platelet-Rich Plasma (PRP) Assessment in Degenerative Discovertebral Complexes (DVC) Using Quantitative MRI at 4.7T: A Preliminary Animal In Vivo Study.Bioengineering (Basel, Switzerland) · 2026Article
- Clinical Outcomes of Two Institution-Specific Cervicothoracic Interlaminar Epidural Steroid Injection Protocols (C7/T1-6 mL vs. T1/T2-8 mL) in Cervical Radiculopathy: A Multicenter Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Functional and Neurological Outcomes After Spine Surgery and Neurorehabilitation for Chronic Discogenic Low Back Pain: A Prospective Observational Pre-Post Study.Healthcare (Basel, Switzerland) · 2026Article
- USP39 inhibits MLKL phosphorylation and deubiquitination to suppress necroptosis of nucleus pulposus cells and attenuate intervertebral disc degeneration.Journal of orthopaedic translation · 2026Article
- Blood and lymphatic vascular remodeling in intervertebral disc degeneration.Frontiers in immunology · 2026Review
- RIPK1-targeted therapy alleviates intervertebral disc degeneration via inhibiting nucleus pulposus PANoptosis.Apoptosis : an international journal on programmed cell death · 2025Article
- Link N Directly Targets IL-1β to Suppress Inflammation and Regulate Sensory Pain in Intervertebral Disc Degeneration.Biomolecules · 2025Article
- EEG alpha/beta features as a biomarker for quantifying pain in patients with lumbar disk herniation.Frontiers in neuroscience · 2025Article
- Short Link N Modulates Inflammasome Activity in Intervertebral Discs Through Interaction with CD14.Biomolecules · 2024Article
- ALKBH5-mediated mCell & bioscience · 2024Article
- Predictive value of S100B and brain derived neurotrophic factor for radiofrequency treatment of lumbar disc prolapse.BMC anesthesiology · 2024Article
- Polymeric Nanoparticles Enable mRNA Transfection and Its Translation in Intervertebral Disc and Human Joint Cells, Except for M1 Macrophages.Pharmaceutics · 2024Article
- Dural tears with cauda equina herniation following percutaneous endoscopic lumbar discectomy: a case report and literature review.Frontiers in surgery · 2024Article
- Development and feasibility of a mindfulness-based dance/movement therapy intervention for chronic low back pain.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Developments and clinical experiences in collagenase chemonucleolysis for lumbar disc herniation: a narrative review.Frontiers in medicine · 2024Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Back pain is the second leading cause of disability among American adults and is currently treated either with conservative therapy or interventional pain procedures. However, the question that remains is whether we, as physicians, have adequate therapeutic options to offer to the patients who suffer from chronic low back pain but fail both conservative therapy and interventional pain procedures before they consider surgical options such as discectomy, disc arthroplasty, or spinal fusion. The purpose of this article is to review the potential novel therapies that are on the horizon for the treatment of chronic low back pain. We discuss medications that are currently in use through different phases of clinical trials (I-III) for the treatment of low back pain. In this review, we discuss revisiting the concept of chemonucleolysis using chymopapain, as the first drug in an intradiscal injection to reduce herniated disc size, and newer intradiscal therapies, including collagenase, chondroitinase, matrix metalloproteinases, and ethanol gel. We also review an intravenous glial cell-derived neurotrophic growth factor called artemin, which may repair sensory nerves compressed by herniated discs. Another new drug in development for low back pain without radiculopathy is a subcutaneous monoclonal antibody acting as nerve growth factor called tanezumab. Finally, we discuss how platelet-rich plasma and stem cells are being studied for the treatment of low back pain. We believe that with these new therapeutic options, we can bridge the current gap between conservative/interventional procedures and surgeries in patients with chronic back pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.